Bayer ups sales targets for top-selling drugs after Monsanto deal

September 20, 2016 5:51 AM

1 0

Bayer ups sales targets for top-selling drugs after Monsanto deal

FRANKFURT German drugmaker Bayer (BAYGn.DE) said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto (MON.N) stirred criticism it might neglect its pharmaceuticals business.

Bayer now expects annual peak sales of more than 5 billion euros ($5.6 billion) for stroke prevention pill Xarelto, jointly sold with Johnson & Johnson (JNJ.N), where it had previously seen about 3.5 billion.

Also read: EU Clears $26 Billion Microsoft-LinkedIn Deal

Read more

To category page

Loading...